Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Receivables (2016 - 2025)

Historic Receivables for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to $162.6 million.

  • CorMedix's Receivables rose 83500.86% to $162.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.6 million, marking a year-over-year increase of 83500.86%. This contributed to the annual value of $51.7 million for FY2024, which is N/A changed from last year.
  • CorMedix's Receivables amounted to $162.6 million in Q3 2025, which was up 83500.86% from $42.9 million recorded in Q2 2025.
  • CorMedix's Receivables' 5-year high stood at $162.6 million during Q3 2025, with a 5-year trough of $2975.0 in Q1 2022.
  • Its 4-year average for Receivables is $27.6 million, with a median of $831771.5 in 2024.
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 9317.75% in 2022, then soared by 597523.52% in 2025.
  • Over the past 4 years, CorMedix's Receivables (Quarter) stood at $45368.0 in 2021, then plummeted by 93.44% to $2975.0 in 2022, then surged by 1736154.89% to $51.7 million in 2024, then soared by 214.74% to $162.6 million in 2025.
  • Its last three reported values are $162.6 million in Q3 2025, $42.9 million for Q2 2025, and $957206.0 during Q1 2025.